Skip to Content
Merck
All Photos(2)

Key Documents

456R-3

Sigma-Aldrich

IDH1 R132H (MRQ-67) Rabbit Monoclonal Antibody

Synonym(s):

Isocitrate dehydrogenase 1

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

UNSPSC Code:
12352203

biological source

rabbit

Quality Level

100
500

conjugate

unconjugated

antibody form

culture supernatant

antibody product type

primary antibodies

clone

MRQ-67, monoclonal

description

For In Vitro Diagnostic Use in Select Regions

form

buffered aqueous solution

species reactivity

human

packaging

vial of 0.1 mL concentrate (456R-34)
vial of 0.1 mL concentrate, Research Use Only (456R-34-RUO)
vial of 0.5 mL concentrate (456R-35)
vial of 1.0 mL concentrate (456R-36)
vial of 1.0 mL concentrate, Research Use Only (456R-36-RUO)
vial of 1.0 mL pre-dilute ready-to-use (456R-37)
vial of 1.0 mL pre-dilute, Research Use Only (456R-37-RUO)
vial of 7.0 mL pre-dilute ready-to-use (456R-38)
vial of 7.0 mL pre-dilute, ready-to-use, Research Use Only (456R-38-RUO)

manufacturer/tradename

Cell Marque™

technique(s)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:100 (concentrated)

isotype

IgG

control

acute myeloid leukemia, astrocytoma, glioblastoma, oligodendroglioma

shipped in

wet ice

storage temp.

2-8°C

visualization

cytoplasmic

Gene Information

human ... IDH1(3417)

Related Categories

General description

Isocitrate dehydrogenase 1 (IDH1) functions as an enzyme in the Krebs (citric acid) cycle and is biologically active in the cytoplasmic and peroxisomal compartments under normal conditions. The occurrence of heterozygous missense mutations at an arginine residue at codon 132 (R132) within the coding region for the substrate binding site of IDH1 has been described to promote oncogenesis in several malignancies. Of the identified mutant variants, a histidine substitution (R132H) is one of the more frequently observed point mutations in certain tumor groups of gliomas. Mutations involving IDH1 have been implicated as early events during gliomagenesis and IDH1 mutation status was incorporated into the 2016 WHO Classification of Tumors of the Central Nervous System as a new parameter for sub-classifying diffuse astrocytic and oligodendrogliomal tumors.3,4 Immunohistochemical identification of IDH1 R132H immunoreactivity can be used as a tool in screening tumors that may be harboring this mutation, such as low grade diffuse and anaplastic astrocytomas, oligodendrogliomas, and secondary glioblastomas.

Quality

United States - IVD
Canada - RUO
European Union - IVD
Japan - RUO

Physical form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide.

Preparation Note

Download the IFU specific to your product lot and format
Note: This requires a keycode which can be found on your packaging or product label.

Other Notes

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Legal Information

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Habibe Kurt et al.
The American journal of surgical pathology, 42(5), 569-577 (2018-04-11)
Isocitrate dehydrogenase 1 (IDH1) and IDH2 mutations occur in a variety of myeloid neoplasms. Immunohistochemistry (IHC)-based direct visualization of mutant clones of hematopoietic cells can be useful for rapid diagnostic screening and for monitoring treatment response. In this study, we
Takuya Watanabe et al.
The American journal of pathology, 174(4), 1149-1153 (2009-02-28)
IDH1 encodes isocitrate dehydrogenase 1, which participates in the citric acid cycle and was recently reported to be mutated in 12% of glioblastomas. We assessed IDH1 mutations in 321 gliomas of various histological types and biological behaviors. A total of
Jörg Balss et al.
Acta neuropathologica, 116(6), 597-602 (2008-11-06)
A recent study reported on mutations in the active site of the isocitrate dehydrogenase (IDH1) gene in 12% of glioblastomas. All mutations detected resulted in an amino acid exchange in position 132. We analyzed the genomic region spanning wild type
David N Louis et al.
Acta neuropathologica, 131(6), 803-820 (2016-05-10)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System is both a conceptual and practical advance over its 2007 predecessor. For the first time, the WHO classification of CNS tumors uses molecular parameters in addition to
Hui Yang et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 18(20), 5562-5571 (2012-10-17)
Genes encoding for isocitrate dehydrogenases 1 and 2, IDH1 and IDH2, are frequently mutated in multiple types of human cancer. Mutations targeting IDH1 and IDH2 result in simultaneous loss of their normal catalytic activity, the production of α-ketoglutarate (α-KG), and

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service